LDLR and familial hypercholesterolemia: PCSK9 mainly regulates the concentration of LDL-C by degrading the LDLR; thus, PCSK9 inhibitors have become a novel effective therapeutic strategy for lipid management in patients with hypercholesterolemia and ACS.